Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of ritonavir-boosted atazavavir (ATV/r) compared with ritonavir-boosted darunavir (DRV/r) or raltegravir in HIV-1 infected patients: The Italian Cohort Naives Antinetrovirals (ICONA) foundation study

Trial Profile

Safety and efficacy of ritonavir-boosted atazavavir (ATV/r) compared with ritonavir-boosted darunavir (DRV/r) or raltegravir in HIV-1 infected patients: The Italian Cohort Naives Antinetrovirals (ICONA) foundation study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir/ritonavir (Primary) ; Darunavir/ritonavir (Primary) ; Raltegravir (Primary) ; Abacavir; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2018 New trial record
    • 01 Mar 2018 Results published in the HIV Clinical Trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top